
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings has demonstrated a strong turnaround in its business, evidenced by reported 11.3% growth in technology and surgical products, primarily driven by robust Rosa placements and effective mergers and acquisitions. The company has outperformed peer growth rates over multiple quarters, supported by a healthy balance sheet and favorable conditions in the orthopedic market. Additionally, the knee segment showcased a solid growth rate of 5.3% globally, reflecting successful product penetration and adoption strategies.
Bears say
Zimmer Biomet Holdings is facing significant challenges as evidenced by its anticipated flat average selling prices (ASP) in FY25 and modest growth headwinds due to selling day differences. The company's growth estimates have been revised downward, with projected FY26 revenue growth at only 5.4% year-over-year and organic growth at a mere 3.1%, highlighting underperformance relative to peers in key segments. Additionally, the firm is grappling with execution difficulties, market share losses, and risks associated with its manufacturing processes, which collectively warrant a discount in valuation compared to its competitors.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares